enGene (ENGN) Short Interest Ratio & Short Volume

Short interest is the volume of enGene shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 42,800 shares of ENGN short. 0.19% of enGene's shares are currently sold short. Learn More on enGene's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.19% of enGene's floating shares are currently sold short.

enGene saw a decline in short interest in March. As of March 15th, there was short interest totaling 42,800 shares, a decline of 29.0% from the previous total of 60,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

enGene currently has issued a total of 50,977,000 shares. Some of enGene's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. enGene currently has a public float of 22,160,000 shares.

0.19% of enGene's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to enGene: Rocket Pharmaceuticals, Inc. (16.95%), Xencor, Inc. (9.15%), Xeris Biopharma Holdings, Inc. (7.88%), Phibro Animal Health Co. (3.60%), Gyre Therapeutics, Inc. (9.41%), Oculis Holding AG (0.11%), Replimune Group, Inc. (13.60%), Cogent Biosciences, Inc. (11.39%), Day One Biopharmaceuticals, Inc. (22.91%), Evolus, Inc. (11.86%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks.

Short selling ENGN is an investing strategy that aims to generate trading profit from enGene as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for enGene occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENGN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENGN, twice per month. The most recent reporting period available is March, 15 2025.